Hundreds of billions of leaders to make money: Hengrui attack innovation, the first imitation collection...

Pharmaceutical Network December 9th, "Research and development of a brother" Hengrui Pharmaceuticals earlier released the first three quarters of 2020 results, thanks to innovative drug-driven, revenue and net profit have double-digit growth.
As one of the domestic head pharmaceutical companies, China Biopharmaceuticals in recent years in the creation of imitation combination of the road has also gone further and further, recently released performance data show that in the outbreak, mining and other factors, the company's first three quarters of revenue and net profit have shown a small decline, but new products, innovative drugs, anti-tumor drugs sales have increased significantly.
Collage "home base": Zhongsheng total assets of more than 60 billion, Hengrui net profit festival high figure 1: In recent years, Hengrui Pharmaceutical's performance and assets (units: billion yuan) Source: Company Annual Report Figure 2: China Biopharmaceuticals performance and assets in recent years (units: billion yuan) Source: Company Annual Report China Biopharmaceutical Subsidiary Including Zhengda Tianqing Pharmaceutical Group, Beijing Ted Pharmaceuticals, Nanjing Zhengda Tianqing Pharmaceuticals, Jiangsu Zhengda Fenghai Pharmaceuticals, Jiangsu Zhengda Qingjiang Pharmaceuticals, Zhengda Pharmaceuticals (Qingdao), Lianyun Hongrun Pharmaceuticals and Shanghai General Pharmaceuticals, etc., as of September 31, 2020, the Group's total assets of more than 66.2 billion yuan.
Hengrui Pharmaceutical Subsidiary company involved in Shanghai Hengrui Pharmaceuticals, Shanghai Shengdi Pharmaceuticals, Chengdu Shengdi Pharmaceuticals, Suzhou Shengdia Biopharmaceuticals, Jiangsu Shengdi Pharmaceuticals, Jiangsu Xinchen Pharmaceuticals, Kaidias Pharmaceuticals, Japan Hengrui, etc., as of September 31, 2020, the Group's total assets of more than 32.5 billion yuan.
from the bottom of the family, China's biopharmaceutical victory! In terms of operating income, China's biopharmaceutical revenue remained above 20 billion yuan in 2018-2019 and reached 18.126 billion yuan in the first three quarters of 2020, while Hengrui Pharmaceuticals' revenue broke through the 20 billion yuan mark in 2019 and reached 19.413 billion yuan in the first three quarters of 2020.
From the profit level, China Biopharmaceuticals after the completion of the acquisition in 2018 to merge Beijing Ted, the full-year return should account for more than 9 billion yuan in profit, less "extra holdings" in 2019, earnings return to normal (2017 earnings of 2.171 billion yuan), but compared with Hengrui, there is still a widening gap, the first three quarters of 2020 the gap between the two sides' net profit is still at 2 billion yuan.
Collage research and development: Hengrui by innovation-driven, Zhongsheng "create imitation combination" Figure 3: In recent years, Hengrui pharmaceutical research and development investment (unit: billion yuan) Source: the company's annual report in recent times, Hengrui 1 new drugs approved clinical news is endless, the industry believes that this is the company ushered in the harvest period performance.
hengrui is taking the innovation-driven route, the high proportion of research and development costs in the industry is well-known.
the first three quarters of 2020, the company's research and development investment has exceeded that of the whole of 2018, and the proportion of research and development investment is higher than that of the whole of 2019.
According to MED2.0 China Drug Review Database data, from 2020 to date, Hengrui and its subsidiaries have been approved clinically 1 new class of drugs involving 86 acceptance numbers (including chemical drugs, biological drugs a total of 23 products).
Figure 4: China's biopharmaceutical research and development investment in recent years (units: 100 million yuan) Source: The company's annual report on China's biopharmaceutical research and development investment has been maintained at about 10%, in the first three quarters of 2020 reached 2.107 billion yuan.
According to MED2.0 China Drug Review Database data, from 2020 to date, the Group's subsidiary Zhengda Tianqing Pharmaceutical Group has been approved clinically 1 new class of drugs involving the acceptance number 9 (including chemical drugs, biological drugs a total of 5 Products), Beijing Ted Pharmaceuticals approved clinical 1 new drug involving acceptance number 2 (1 chemical), in addition, Beijing Ted Pharmaceuticals Pribarin slow release tablets 3 imitations were also approved clinical, the product is currently no domestic generic drugs approved for market.
harvest: Hengrui 1 class of new drugs bright eyes, Zhongsheng took a number of imitation table 1:2020 so far Hengrui approved for listing of new products Source: Minet MED2.0 China Drug Review Database 2020 opening, Hengrui issued a notice that the company's first class of new drugs injected with toluene sulphate Lun was approved for the market, the product is a short-acting GABAA subjector astration agent, approved indications for routine gastroscopy sedation, July 1, the company announced that the product "colonoscopy sedation" indications were approved, the company has invested in the research and development project cost about 79.21 million yuan.
In addition, Hengrui was approved in 2019 to market a new class of drugs injected with Karelli pearl monoantibodies are humanized anti-PD-1 monoclonal antibodies, the initial approved adaptation is Hodgkin's lymphoma, in 2020 added three new allergies, respectively, advanced hepatocellular carcinoma, advanced esophageal squamous cancer and non-squamous non-small cell lung cancer.
health-care talks in the fourth quarter of this year are among the most recent hot topics, and the two new Class 1 drugs are expected to be involved.
Earlier, the company's first class of new drug Malay acid pyridoxine tablets through health insurance negotiations into the 2019 version of the national health insurance catalog after the sales surge, 2020H1 in China's urban public hospitals, county-level public hospitals, urban communities and township hospitals (referred to as China's public medical institutions) terminal sales of nearly 500 million yuan.
we wait for the results to see if we can build on this year.
generic drugs, the first imitation of the ammonium bromide injection was successfully won by Hengrui.
May 2018, the company submitted and accepted applications for drug registration, which was included in the priority review in the same year.
The product is an anticholinel energy drug, when reversing the non-depolarized muscle relaxant induced neuromuscular block, the drug can antagonize choline energy drugs, such as The anti-choline action of Xins Ming's exodus, the product has been invested in research and development costs of about 14.89 million yuan.
earlier this year, china has been approved for listing of ammonium Glon bromide tablets and Glon ammonium bromide inhalation powder mist capsules, in November this year, Chengdu Yuandong Biopharmaceutical became the second approved listed enterprises.
table 2:2020 to date China Biopharmaceuticals approved for listing of new products Source: Minet MED2.0 China Drug Review Database 2020 to date, a total of 20 products approved for listing in China Biopharmaceuticals, six of which are the first imitation, in addition, Monrust sodium particles, Celexib capsules, Kagrese net tablets, shagritin tablets have won the second domestic.
Inhalation with Budinide suspension is a strong local anti-inflammatory effect of inhalation of glucoticoids, drugged through negatifiers, clinically used to treat bronchial asthma, can also replace or reduce oral steroid treatment.
Zhengda Tianqing Pharmaceutical Group won the first domestic imitation approved and treated as a review, completely breaking AstraZeneta's monopoly situation.
four types of imitations of Mrs. Shenzhen Pharmaceuticals were approved in July this year, becoming the second in China.
pomadamine capsule is a new generation of immunomodulating agents after salidamine and lenamine, which can inhibit the growth of hematologic tumor cells and induce apoptosis.
Zhengda Tianqing Pharmaceutical Group won the domestic first imitation and as a review, the heavyweight product was approved for listing, is conducive to the Group to improve the field of myeloma product layout.
Fluorovirus group injection is a new estrogen-like antagonist that blocks the nutritional effects of estrogen, clinical studies show that the product is currently considered to be the only estrogen-like inhibitor that is still effective after his moxifen treatment is ineffective, and has fewer side effects, good tolerance and other advantages, the product was included in the "first batch of encouraging generic drugs list."
Group's fluorovis group injection is the implementation of export and domestic double-report varieties, has been approved for listing in the United States and Germany respectively, Zhengda Tianqing Pharmaceutical Group took the domestic first imitation and as a review.
N quentinin novovir tablets in the enqutabin and fumarate novovir difficide two active ingredients are high-efficiency antiretroviral drugs, the product is a single tablet, with treatment simplification, significant efficacy, high patient compliance, low drug resistance and so on, in 2017 was included in the national health insurance directory, Zhengda Tianqing Pharmaceutical Group took the first domestic imitation and evaluation.
four-class imitation of Anhui Baker Biopharmaceutical was approved in October this year, becoming the second in China.
phosphoric acid siglitin tablets are a powerful, highly selective lipidase-4 (DPP-4) inhibitor used to improve blood sugar control in people with type 2 diabetes.
Zhengda Tianqing Pharmaceutical Group won the domestic first imitation and as a review, Guangdong Dongsian Pharmaceuticals 4 types of imitations were approved in August this year, becoming the second in the country.
Dabiga group ester capsules are β-alanine coagulase inhibitors used to prevent stroke and systemic embolism in patients with non-valve atrial fibrillation, to treat acute deep vein thyroid formation and pulmonary embolism, and to prevent recurrence.
Zhengda Tianqing Pharmaceutical Group won the domestic first imitation and as if it had been evaluated, the approval of the product will further consolidate the Group's dominant position in the field of anticoagulants.
Collage: Zhongsheng 16 products won the bid, by force to play a good marketing combination punch in recent years, with volume procurement has become the industry's top priority, collection of normalization to bring benefits to patients, but also let the market pattern into the era of big shuffle, head pharmaceutical companies by virtue of strong strength, has repeatedly become the opening scene of the dazzling star.
At present, the national collection has carried out three batches, involving a total of 112 varieties (125 by product name), China Biopharmaceuticals from the 4 plus 7 pilot began to participate in a total of 16 products winning the bid, and Hengrui from the expansion of the alliance, a total of 9 products won the bid.
Table 3: National Collection of winning products Source: Shanghai Sunshine Pharmaceutical Procurement Network, Mi Net finishing China Biopharmaceuticals in the third quarter of the report mentioned that three batches of national collection involving the company's major products, for a longer time to market, there are a number of competitive manufacturers such as run people (Entika) Verbe dispersion tablets), Elemping (Ebershatan hydrochlorochlorophenic tablets), Toto (Rishuvastatin calcium tablets), Kaiser (fluorobilofen injections), etc., the collection price reduction is large, although there is a significant increase in sales volume, but the impact on overall revenue and profit is still significant.
For newly listed products such as qingcoshu (acetic acid abitorn tablets), Ji to (Gifeitini tablets), Vistom (injection with azatrosin tablets), Abenin (apixaban tablets), Perishu (Tygrilo tablets), Taiyu (tingeacid tofatib tablets), Surigi (Selesib capsules) and other striped products after the purchase of significantly faster.
Group actively respond to the impact of volume procurement on the marketing cost structure, quickly transfer academic and promotional input to new products, and use the volume of procurement to play a good marketing mix with the selected products associated with the product, achieved better results.
Hengrui participated in the collection of 9 products, hydrochloric acid quretaquine slow release tablets, acetic acid abitron tablets, injection with yew alcohol (albumin binding type) for the newly approved listed products, with the volume of procurement after the product significantly accelerated.
among them, the new base injection with yew alcohol (albumin binding type) the original winning market was finally divided between Hengrui and stone medicine, the additional harvest of 5 provinces of procurement also greatly improved Hengrui's market share.
Hengrui has now reviewed / the same review of the product has 21, and China Biopharmaceutical has been reviewed / the same evaluation of the product has 44.
the fourth batch of countries recently hotly debated will come? There is no exact news, but there is no doubt that the bidding site will certainly appear in the presence of these two giants, the hospital market this big cake lost a pity.
: Company's annual report, MiNet database review data statistics as of December 3, 2020, if there are errors, please point out.
。